Conversion.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 17101927.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An important aspect of assessing the efficacy of the outcome of the primary and secondary treatment trials concerns the topic of conversion. That is, how does one assess an end point such as the transition from normal to mild cognitive impairment (MCI) or the progression of MCI to Alzheimer disease (AD)? These can be difficult issues, but as more is learned about the intermediate states such as MCI, criteria can be developed.
Medical subject headings
- Alzheimer Disease
- Cognition Disorders